Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types

Michael D. Iglesia; Joel S. Parker; Katherine A. Hoadley; Jonathan S. Serody; Charles M. Perou; Benjamin G. Vincent

doi:10.1093/jnci/djw144

Abstract

These data support existing studies suggesting that in diverse tissue types, heterogeneous immune infiltrates are present and typically portend an improved prognosis. In some tumor types, BCR diversity was also associated with survival. Quantitative genomic signatures of immune cells warrant further testing as prognostic markers and potential biomarkers of response to cancer immunotherapy.

Keywords

CD8Immune systemMelanomaBiologyHazard ratioTumor microenvironmentBreast cancerCancer researchAdenocarcinomaTumor-infiltrating lymphocytesPathologyCancerMedicineOncologyImmunologyInternal medicineConfidence interval

MeSH Terms

B-LymphocytesGene ExpressionGenomicsHumansLymphocytesTumor-InfiltratingMacrophagesNeoplasmsPrognosisRNAMessengerReceptorsCell SurfaceSurvival RateT-LymphocytesTumor Microenvironment

Affiliated Institutions

Related Publications

Comprehensive analyses of tumor immunity: implications for cancer immunotherapy

Bo Li , Eric A. Severson , Jean‐Christophe Pignon +10 more

Understanding the interactions between tumor and the host immune system is critical to finding prognostic biomarkers, reducing drug resistance, and developing new therapies. Nov...

2016 Genome biology 2686 citations

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma

Claudio G. Clemente , Martín C. Mihm , Rosaria Bufalino +3 more

We demonstrated that when categories of tumor infiltrating lymphocytes are strictly defined, they indeed have very strong predictive value for primary cutaneous melanomas with a...

1996 Cancer 1120 citations

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Janis M. Taube , Alison Klein , Julie R. Brahmer +7 more

Abstract Purpose: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response could guide pat...

2014 Clinical Cancer Research 2295 citations

Intraepithelial CD8<sup>+</sup>tumor-infiltrating lymphocytes and a high CD8<sup>+</sup>/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

Eiichi Sato , Sara H. Olson , Jiyoung Ahn +15 more

In a recent report, [Zhang et al. (2003) N. Engl. J. Med. 348, 203–213], the presence of CD3 + tumor-infiltrating lymphocytes (TILs) was found to correlate with improved surviva...

2005 Proceedings of the National Academy o... 2340 citations

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Yuanyuan Zhang , Zemin Zhang

Abstract Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) ...

2020 Cellular and Molecular Immunology 2559 citations

Publication Info

Year: 2016
Type: article
Volume: 108
Issue: 11
Pages: djw144-djw144
Citations: 361
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

361

OpenAlex

Influential

303

CrossRef

Cite This

APA Style

                            
                                
                                    Michael D. Iglesia, 
                                
                                    Joel S. Parker, 
                                
                                    Katherine A. Hoadley
                                
                                et al.
                            
                            (2016). 
                            Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. 
                            JNCI Journal of the National Cancer Institute
                            , 108
                            (11)
                            , djw144-djw144.
                            https://doi.org/10.1093/jnci/djw144
                        

Identifiers

DOI: 10.1093/jnci/djw144
PMID: 27335052
PMCID: PMC5241901

Data Quality

Data completeness: 86%